Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Merck
Mallinckrodt
UBS
Harvard Business School
US Department of Justice
Deloitte
AstraZeneca
Fuji
Moodys

Generated: August 21, 2017

DrugPatentWatch Database Preview

COMETRIQ Drug Profile

« Back to Dashboard

Which patents cover Cometriq, and when can generic versions of Cometriq launch?

Cometriq is a drug marketed by Exelixis and is included in one NDA. There are two patents protecting this drug.

This drug has ninety patent family members in twenty-eight countries.

The generic ingredient in COMETRIQ is cabozantinib s-malate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.

Summary for Tradename: COMETRIQ

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list49
Clinical Trials: see list20
Drug Prices:see details
DailyMed Link:COMETRIQ at DailyMed

Pharmacology for Tradename: COMETRIQ

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exelixis
COMETRIQ
cabozantinib s-malate
CAPSULE;ORAL203756-001Nov 29, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Exelixis
COMETRIQ
cabozantinib s-malate
CAPSULE;ORAL203756-002Nov 29, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Exelixis
COMETRIQ
cabozantinib s-malate
CAPSULE;ORAL203756-001Nov 29, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Exelixis
COMETRIQ
cabozantinib s-malate
CAPSULE;ORAL203756-002Nov 29, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Exelixis
COMETRIQ
cabozantinib s-malate
CAPSULE;ORAL203756-001Nov 29, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: COMETRIQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,155,378► Subscribe
8,497,284C-met modulators and method of use► Subscribe
8,178,532c-Met modulators and method of use► Subscribe
8,067,436c-Met modulators and methods of use► Subscribe
8,476,298c-Met modulators and method of use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: COMETRIQ

Country Document Number Estimated Expiration
Japan2014055190► Subscribe
CroatiaP20140563► Subscribe
Australia2017200555► Subscribe
Denmark2392564► Subscribe
Hong Kong1164312► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: COMETRIQ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000091Germany► SubscribePRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321
90053-4Sweden► SubscribePRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/13/890 20140326
C0067France► SubscribePRODUCT NAME: CABOZANTINIB ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE COUVERTE PAR LE BREVET DE BASE,INCLUANT SES SELS PHARMACEUTIQUEMENT EQUIVALENTS.; REGISTRATION NO/DATE: EU/1/13/890 20140326
00678Netherlands► SubscribePRODUCT NAME: CABOZANTINIB EN ELKE THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, WAARONDER FARMACEUTISCH AANVAARDBARE ZOUTEN; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
508Luxembourg► SubscribePRODUCT NAME: CABOZANTINIB ET TOUTES LES FORMES THERAPEUTIQUEMENT EQUIVALENTES QUI EN DERIVENT TELLES QUE PROTEGEES PAR LE BREVET DE BASE, Y COMPRIS LES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140326
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Argus Health
Queensland Health
UBS
Dow
Boehringer Ingelheim
Farmers Insurance
Merck
QuintilesIMS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot